mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-ASC-2553mimmun-2553Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESДинамика IgG-антител против RBD участка S-белка SARS-CoV-2 после введения CoronaVac: длительное наблюдениеAnti-SARS-CoV-2 spike receptor binding domain (S-RBD) IgG antibodies following CoronaVac administration: a longitudinal study. Anti-SARS-CoV-2 S-RBD IgG antibodieshttps://orcid.org/0000-0002-2081-180XЛианаФ.LianaPh.

Лиана Фей – заведующая кафедрой клинической патологии, медицинский факультет, Университет Шривиджая – Центральная больница общего профиля доктора Мохаммада Хусина.

30126, Палембанг, Южная Суматера

Тел.: +62 711 373438

Факс: +62 711 373438

Phey Liana - MD, PhD student in Biomedical Science Program, Faculty of Medicine, Sriwijaya University, Palembang, Indonesia, Clinical Pathologist graduated from the Faculty of Medicine, University of Indonesia, Jakarta; Head, Department of Clinical Pathology, Faculty of Medicine, Sriwijaya University – Dr. Mohammad Hoesin General Hospital.

Palembang South Sumatera 30126

Phone: +62 711 373438

Fax: +62 711 373438

pheyliana@fk.unsri.ac.idФертилитаС.FertilitaS.

Фертилита Сойлия – преподаватель кафедры гистологии, медицинский факультет, Университет Шривиджая – Центральная больница общего профиля доктора Мохаммада Хусина.

Палембанг

Soilia Fertilita - MD, Magister in Immunology from Postgraduate Program, Universitas Airlangga, Surabaya; Lecturer in the Department of Histology, Faculty of Medicine, Department of Histology, Faculty of Medicine, Sriwijaya University – Dr. Mohammad Hoesin General Hospital.

Palembang

soilia.fertilita@fk.unsri.ac.idАмалиаЭ.AmaliaE.

Амалиа Элла – преподаватель, заведующая кафедрой микробиологии, медицинский факультет, Университет Шривиджая – Центральная больница общего профиля доктора Мохаммада Хусина.

Палембанг

Ella Amalia - MD, Magister in Biomedical Science from Postgraduate Program, Head of Department of Microbiology and Lecturer, Faculty of Medicine, Sriwijaya University – Dr. Mohammad Hoesin General Hospital.

Palembang

ellaamalia@fk.unsri.ac.idЛарасатиВ.LarasatiV.

Ларасати Вени – преподаватель, заведующая кафедрой гистологии, медицинский факультет, Университет Шривиджая – Центральная больница общего профиля доктора Мохаммада Хусина.

Палембанг

Veny Larasati - MD, Magister in Biomedical Science from Postgraduate Program, Universitas Udayana, Bali; Head of Department of Histology and Lecturer, Faculty of Medicine, Sriwijaya University – Dr. Mohammad Hoesin General Hospital.

Palembang

venylarasati@fk.unsri.ac.idРасидР. С.П.RasyidR. S.P.

Расид Риана Сари Пуспита – преподаватель кафедры гистологии, медицинский факультет, Университет Шривиджая – Центральная больница общего профиля доктора Мохаммада Хусина.

Палембанг

Riana Sari Puspita Rasyid - MD, Magister in Biomedical Science from Postgraduate Program, Lecturer in the Department of Histology, Faculty of Medicine, Sriwijaya University – Dr. Mohammad Hoesin General Hospital.

Palembang

rianasaripuspita@fk.unsri.ac.idЗулиссетинаЭ. Ф.ZulissetianaE. F.

Зулиссетина Эка Фебри – преподаватель кафедры физиологии, медицинский факультет, Университет Шривиджая – Центральная больница общего профиля доктора Мохаммада Хусина.

Палембанг

Eka Febri Zulissetiana - MD, Magister in Biomedical Science from Postgraduate Program, Lecturer in The Department of Physiology, Faculty of Medicine, Sriwijaya University – Dr. Mohammad Hoesin General Hospital.

Palembang

ekafebrizulissetiana@unsri.ac.idСаблоакР.SabloakR.

Саблоак Рохан – студент медицинского факультета, Университет Шривиджая – Центральная больница общего профиля доктора Мохаммада Хусина.

Палембанг

Rohan Sabloak - Undergraduate Medical Student, Faculty of Medicine, Sriwijaya University – Dr. Mohammad Hoesin General Hospital.

Palembang

rohansabloak1@gmail.comСариЗ. У.SariZ. U.

Сари Закийя Ульфа – студент медицинского факультета, Университет Шривиджая – Центральная больница общего профиля доктора Мохаммада Хусина.

Палембанг

Zakiyyah Ulfa Sari - Undergraduate Medical Student, Faculty of Medicine, Sriwijaya University – Dr. Mohammad Hoesin General Hospital.

Palembang

zakiyyahUsariii@gmail.comУниверситет Шривиджая – Центральная больница общего профиля доктора Мохаммада ХусинаИндонезияSriwijaya University – Dr. Mohammad Hoesin General HospitalIndonesia202306022023251215222Copyright © Лиана Ф., Фертилита С., Амалиа Э., Ларасати В., Расид Р.С., Зулиссетина Э.Ф., Саблоак Р., Сари З.У., 20232023Лиана Ф., Фертилита С., Амалиа Э., Ларасати В., Расид Р.С., Зулиссетина Э.Ф., Саблоак Р., Сари З.У.Liana P., Fertilita S., Amalia E., Larasati V., Rasyid R.S., Zulissetiana E.F., Sabloak R., Sari Z.U.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/2553

Сообщений о титрах антител после введения CoronaVac по-прежнему мало, особенно когда речь идет об эффективности CoronaVac после вакцинации среди населения Индонезии. Целью данного исследования является определение эффективности вакцинации против COVID-19 путем сравнения уровней IgG против S1 субъединицы RBD SARS-CoV-2 после первой и второй вакцинации. Исследователи собрали образцы венозной крови у участников после того, как они получили вакцину CoronaVac 600 SU/0,5 мл с двумя разными интервалами (14 дней и 28 дней). Кровь брали дважды (после первой и второй вакцинации) и тестировали на антитела (значение положительного обнаружения антител 50 AU/мл). Парные данные были проанализированы с использованием критерия Уилкоксона (числового) или критерия Макнемара (категориального). Средние уровни IgG1  в 14-дневном интервале между дозами вакцины составляли 64,40 AU/мл, а уровни IgG2 составляли 886,10 AU/мл. При этом средний уровень IgG1 составил 146,10, а уровень IgG2 – 688,00 AU/мл        в группе с 28-дневным интервалом между дозами вакцины. После первой вакцинации 60,00% обследованные имели положительный уровень IgG, который увеличился до 98,57% после второй вакцинации. После вакцинации полной дозой все участники имели достоверно более высокие уровни антител. Эффект был сильнее в группе, получавшей вакцину с 14-дневным интервалом. Также было показано, что CoronaVac увеличивает встречаемость антител у участников исследования.

Reports on antibody titers following CoronaVac administration are still scarce, particularly when it comes to the post-vaccination effectiveness of CoronaVac in the Indonesian population. The purpose of  this study is to determine the efficacy of COVID-19 vaccination by comparing the IgG levels against the S1 subunit of SARS-CoV-2 RBD after the first and second vaccinations. The researchers collected venous blood samples from participants after they received the CoronaVac 600 SU/0.5 mL vaccine at two different intervals (14 days and 28 days). Blood was drawn twice (after the first and second vaccinations) and tested for antibodies (positive antibody detection value of 50 AU/mL). Paired data were analyzed by using either the Wilcoxon test (numerical) or the McNemar test (categorical). The median IgG1 levels in the 14-day interval between vaccine doses were 64.40 AU/mL and IgG2 levels were 886.10 AU/mL. Meanwhile, the median IgG1 level was 146.10, and IgG2 level was 688.00.AU/mL in the group with a 28-day interval between vaccine doses. After the first vaccination, 60.00 % of study subjects had positive IgG levels, which increased to 98.57% after the second vaccination. Following the full-dose vaccination, all participants had higher antibody levels, and considered significant. The effect was stronger in the group that received the vaccine at 14-day intervals. CoronaVac has also been shown to increase the prevalence of detectable antibody positivity in study participants.

антителоусловная единицаCoronaVacрецептор-связывающий доменSARS-CoV-2antibodyarbitrary unit (AU)CoronaVacreceptor binding domainSARS-CoV-2This study was supported by the funding from Sriwijaya University Faculty of Medicine (grant number: 0330/UN9.FK/TU.SK/2021).ReferencesAkpolat T., Uzun O. Reduced mortality rate after coronavac vaccine among healthcare workers. J. Infect., 2021, Vol. 83, no. 2, pp. e20-e21.Speiser DE, Bachmann MF. Covid-19: Mechanisms of vaccination and immunity. Vaccines, 2020, Vol. 8, no. 3, pp. 404.Bayram A., Demirbakan H., Karadeniz P.G., Erdoğan M., Koçer I. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in health care workers. J. Med. Virol., 2021, Vol. 93, no. 9, pp. 5560-5567.Min L, Sun Q Antibodies and Vaccines Target RBD of SARS-CoV-2. Front Mol Biosci, 2021, Vol. 8, pp. 247.Binay U.D., Karakecili F., Binali E., Barkay O., Gul O., Mertoglu C. Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report. J. Antivir. Antiretrovir., 2021, Vol. 13, no. S18, 005. doi: 10.21203/rs.3.rs-388073/v2.Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines, 2021, Vol . 6, no. 1, pp. 1–17.Cabinet Secretariat of the Republic of Indonesia. (2021) BPOM allows use of sinovac vaccine for children aged 6-11. [Cited 8 December 2021]. Available from: https://setkab.go.id/en/bpom-allows-use-of-sinovac-vaccine-for-children-aged-6-11/.Rego GNA, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, et al. Current clinical trials protocols and the global effort for immunization against sars-cov-2. Vaccines, 2020, Vol. 8, no. 3, pp. 474.Calina D., Docea A.O., Petrakis D., Egorov A.M., Ishmukhametov A.A., Gabibov A.G. Towards effective COVID19 vaccines: Updates, perspectives and challenges. Int. J. Mol. Med., 2020, Vol. 46, no. 1, pp. 3-16.Ganji K.S., Mohammadzadeh I., Mohammadnia-Afrouzi M., Ebrahimpour S., Shahbazi M. Factors affecting immune responses to vaccines. Gazz Medica Ital Arch per le Sci Mediche, 2018, Vol. 177, no. 5, pp. 219-228.Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, et al. Towards effective COVID‑19 vaccines: Updates, perspectives and challenges. Int J Mol Med, 2020, Vol. 46, no. 1, pp. 3–16.Jara A., Undurraga E.A., González C., Paredes F., Fontecilla T., Jara G. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med., 2021, Vol. 385, no. 10, pp. 875-884.Krause PR, Gruber MF. Emergency use authorization of Covid vaccines—safety and efficacy follow-up considerations. N Engl J Med, 2020, Vol. 383, no. 19, pp. e107.Keskin A.U., Bolukcu S., Ciragil P., Topkaya A.E. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J. Med. Virol., 2022, Vol. 94, no. 1, pp. 39-41.Munro C. Covid-19: 40% of patients with weakened immune system mount lower response to vaccines. BMJ. 2021, Vol. 374, pp. n2098.Krause P.R., Gruber M.F. Emergency use authorization of Covid vaccines – safety and efficacy follow-up considerations. N. Engl. J. Med., 2020, Vol. 383, no. 19, e107. doi: 10.1056/NEJMp2031373.Nugraha RR, Miranda AV, Ahmadi A, Lucero-Prisno DE. Accelerating Indonesian COVID-19 vaccination rollout: a critical task amid the second wave. Trop Med Health, 2021, Vol. 49, no. 1, pp. 76.Kyriakidis N.C., López-Cortés A., González E.V., Grimaldos A.B., Prado E.O. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines, 2021, Vol . 6, no. 1, 28. doi: 10.1038/s41541-021-00292-w.Wilder-Smith A, Mulholland K. Effectiveness of an Inactivated SARS-CoV-2 Vaccine. N Engl J Med, 2021, Vol. 385, pp. 946–8.Lippi G., Henry B.M., Plebani M. Anti-SARS-CoV-2 Antibodies testing in recipients of COVID-19 vaccination: why, when, and how? Diagnostics, 2021, Vol. 11, no. 6, 941. doi: 10.3390/diagnostics11060941.Cabinet Secretariat of the Republic of Indonesia. (2021) BPOM Allows Use of Sinovac Vaccine for Children Aged 6-11. [Cited 8 December 2021]. Available from: https://setkab.go.id/en/bpom-allows-use-of-sinovac-vaccine-for-children-aged-6-11/.Melgoza-González E.A., Hinojosa-Trujillo D., Reséndiz-Sandoval M., Mata-Haro V., Hernández-Valenzuela S., García-Vega M., Bravo-Parra M., Arvizu-Flores A.A., Valenzuela O., Velázquez E., Soto-Gaxiola A., Gómez-Meza M.B., Pérez-Jacobo F., Villela L., Hernández J. Analysis of IgG, IgA and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines. Transbound. Emerg. Di.s, 2021. doi: 10.1111/tbed.14344.Ganji KS, Mohammadzadeh I, Mohammadnia-Afrouzi M, Ebrahimpour S, Shahbazi M. Factors affecting immune responses to vaccines. Gazz Medica Ital Arch per le Sci Mediche, 2018, Vol. 177, no. 5, pp. 219–28.Min L., Sun Q. Antibodies and Vaccines Target RBD of SARS-CoV-2. Front. Mol. Biosci., 2021, Vol. 8, 671633. doi: 10.3389/fmolb.2021.671633.Melgoza-González EA, Hinojosa-Trujillo D, Reséndiz-Sandoval M, Mata-Haro V, Hernández-Valenzuela S, García-Vega M, Bravo-Parra M, Arvizu-Flores AA, Valenzuela O, Velázquez E, Soto-Gaxiola A, Gómez-Meza MB, Pérez-Jacobo F, Villela L, Hernández J. Analysis of IgG, IgA and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines. Transbound Emerg Dis, 2021, pp. 1-12. Doi: 10.1111/tbed.14344.Munro C. Covid-19: 40% of patients with weakened immune system mount lower response to vaccines. BMJ, 2021, Vol. 374, n2098. doi: 10.1136/bmj.n2098.Ulhaq ZS, Soraya GV, Indriana K, Devitasari R, Pradiptha IPY, Zulfikar DB, Uxiana V, Zulkarnain, Rachma LN, Arisanti D. The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine. J Med Virol, 2022, Vol. 94, pp. 829-32.Nugraha R.R., Miranda A.V., Ahmadi A., Lucero-Prisno D.E. Accelerating Indonesian COVID-19 vaccination rollout: a critical task amid the second wave. Trop. Med. Health, 2021, Vol. 49, no. 1, 76. doi: 10.1186/s41182-021-00367-3.Bayram A, Demirbakan H, Karadeniz PG, Erdoğan M, Koçer I. Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in health care workers. J Med Virol, 2021, Vol. 93, no. 9, pp. 5560–5567.Ranzani O.T., Hitchings M.D.T., Dorion M., D’Agostini T.L., de Paula R.C., de Paula O.F.P. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ, 2021, Vol. 374, n2015. doi: 10.1136/bmj.n2015.Akpolat T, Uzun O. Reduced mortality rate after coronavac vaccine among healthcare workers. J Infect, 2021, Vol. 83, no. 2, pp. e20–1.Rego G.N.A., Nucci M.P., Alves A.H., Oliveira F.A., Marti L.C., Nucci L.P. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines, 2020, Vol. 8, no. 3, 474. doi: 10.3390/vaccines8030474.Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med, 2021, Vol. 385, no. 10, pp. 875–84.Speiser D.E., Bachmann M.F. Covid-19: Mechanisms of vaccination and immunity. Vaccines, 2020, Vol. 8, no. 3, 404. doi: 10.3390/vaccines8030404.Binay UD, Karakecili F, Binali E, Barkay O, Gul O, Mertoglu C. Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report. J Antivir Antiretrovir, 2021, Vol. 13, no. S18, pp. 005.Tanriover M.D., Doğanay H.L., Akova M., Güner H.R., Azap A., Akhan S. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 2021, Vol. 398, no. 10296, pp. 213-222.Lippi G, Henry BM, Plebani M. Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How? Diagnostics, 2021, Vol. 11, no. 6, pp. 941.Ulhaq Z.S., Soraya G.V., Indriana K., Devitasari R., Pradiptha I.P.Y., Zulfikar D.B., Uxiana V., Zulkarnain, Rachma L.N., Arisanti D. The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine. J. Med. Virol., 2022, Vol. 94, no. 3, pp. 829-832.Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, Vol. 21, no. 2, pp. 181–92.Wilder-Smith A., Mulholland K. Effectiveness of an Inactivated SARS-CoV-2 Vaccine. N. Engl. J. Med., 2021, Vol. 385, pp. 946-948.Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 2021, Vol. 398, no. 10296, pp. 213–22.Zhang Y., Zeng G., Pan H., Li C., Hu Y., Chu K. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis., 2021, Vol. 21, no. 2, pp. 181-192.Ranzani OT, Hitchings MDT, Dorion M, D’Agostini TL, de Paula RC, de Paula OFP, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ, 2021, Vol. 374, pp. n2015.Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol, 2022, Vol. 94, no. 1, pp. 39-41.Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol, 2022, Vol. 94, no. 1, pp. 39-41.

The authors declare that there are no conflicts of interest present.